Replies to post #174411 on NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

.... while they’re presenting data that indicates a cure for 20-30% of all GBM diagnoses.

I don't know. Results look consistent with the Standard of Care (Stupp Protocol).
Here's a dataset UCLA researchers used as a comparator (from a KaiserP database).

The DCVax trial is very likely heavily weighted with RPA Class III and IV patients.

The blue line below is the Stupp protocol (chemorad followed by maintenance Chemo.)

If you add DCVax to that and get the same results doesn't that suggest DCVax does nothing?

Or, using your words, the Stupp protocol "cures 20-30%"

[VuBru]

Photonic -

Unfortunately, they aren’t as remarkable as the unblinded results of this 11 year trial are shaping up to be.

Unless every patient died right after the scrub of last spring's data, which this new paper is based on, the total OS values and ultimate unblinded DCVAX group OS values have to improve from this paper on final analysis - 90% of patients got the drug and many have lived another year. If correct, the OS reported in this blinded paper is the lower limit on what we should see in the unblinded final analysis. This seems to justify the company's decision to stretch the trial out as long as possible.